

CLAIMS

1. A method of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof, wherein reboxetine is administered at least once daily for at least three weeks, wherein, two weeks from the beginning of treatment, the human being
5 experiences a reduction in the number of cataplexy attacks in a week, a reduction in the Epworth Sleepiness Scale score, a decrease in the cataplexy subscore on the Ullanlinna Narcolepsy Scale (NUS), or a reduction in the Maintenance of Wakefulness Test score as a result of the treatment.
2. Use of reboxetine in the manufacture of a medicament for the treatment of
10 narcolepsy with cataplexy, wherein reboxetine is administered at least once daily for at least three weeks.
3. A kit comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being, wherein reboxetine is administered at least once daily for at least three weeks.
- 15 4. The method, the use, or the kit of claim 1, 2, or 3, wherein reboxetine is administered twice daily, wherein a first dosage form is administered in the morning and a second dosage form is administered about 2 hours to about 6 hours later.
5. The method, the use, or the kit of claim 4, wherein the second dosage form is administered about 2 hours to about 3 hours after the first dosage form.
- 20 6. The method, the use, or the kit of claim 4, wherein the second dose is administered about 3 hours to about 4 hours after the first dosage form.
7. The method, the use, or the kit of claim 4, wherein the second dosage form is administered about 4 hours to about 5 hours after the first dosage form.
8. The method, the use, or the kit of claim 4, wherein the second dosage form is
25 administered about 5 hours to about 6 hours after the first dosage form.
9. The method, the use, or the kit of claim 1, wherein a single dosage form is administered daily, wherein the single dosage form contains a first release component comprising reboxetine and a second release component comprising reboxetine, wherein the first release component provides a first local maximum in the plasma concentration of
30 reboxetine and the second release component provides a second local maximum in the plasma concentration of reboxetine, wherein the first local maximum in the plasma

concentration of reboxetine occurs about 2 to about 6 hours before the second local maximum in the plasma concentration of reboxetine.

10. The method, the use, or the kit of claim 9, wherein the second local maximum in the plasma concentration of reboxetine occurs about 2 to about 3 hours after the first local
5 maximum in the plasma concentration of reboxetine.

11. The method, the use, or the kit of claim 9, wherein the second local maximum in the plasma concentration of reboxetine occurs about 3 to about 4 hours after the first local maximum in the plasma concentration of reboxetine.

12. The method, the use, or the kit of claim 9, wherein the second local maximum in the
10 plasma concentration of reboxetine occurs about 4 to about 5 hours after the first local maximum in the plasma concentration of reboxetine.

13. The method, the use, or the kit of claim 9, wherein the second local maximum in the plasma concentration of reboxetine occurs about 5 to about 6 hours after the first local maximum in the plasma concentration of reboxetine.

14. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, 12, or 13,
15 wherein the human being is selected for not suffering from depression.

15. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14, the dose amount of reboxetine is increased for 1 to 7 days, and then maintained constant at a total daily dose of about 0.006 mmol to about 0.01 mmol.

16. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15,
20 wherein the dose amount of reboxetine is increased for 1 to 7 days, and then maintained constant at a total daily dose of about 0.01 mmol to about 0.02 mmol.

17. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15,
25 wherein the dose of reboxetine is increased for 1 to 7 days, and then maintained constant at a total daily dose of about 0.02 mmol to about 0.03 mmol.

18. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, wherein the dose of reboxetine is increased for 1 to 7 days, and then maintained constant at a total daily dose of about 0.03 mmol to about 0.04 mmol.

19. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, wherein the dose of reboxetine is increased for 1 to 7 days, and then maintained constant at a total daily dose of about 0.04 mmol to about 0.05 mmol.
20. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, wherein the dose of reboxetine is increased for 1 to 7 days, and then maintained constant at a total daily dose of about 0.05 mmol to about 0.06 mmol.
21. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, wherein the dose of reboxetine is increased for 1 to 7 days, and then maintained constant at a total daily dose of about 0.06 mmol to about 0.07 mmol.
22. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, wherein the dose of reboxetine is increased for 1 to 7 days, and then maintained constant at a total daily dose of about 0.07 mmol to about 0.08 mmol.
23. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22, wherein the reboxetine is in a dosage form and the dosage form contains about 5 mg of reboxetine.
24. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22, wherein the reboxetine is in a dosage form and the dosage form contains about 10 mg of reboxetine.
25. The method, the use, or the kit of claim 23, wherein the dosage form is administered once daily or twice daily for at least three weeks.
26. The method, the use, or the kit of claim 24, wherein the dosage form is administered once daily or twice daily for at least three weeks.
27. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26, wherein the human being experiences an increase in sleep latency on the multiple sleep latency test (MSLT).
28. The method, the use, or the kit of claim 27, wherein the human being experiences an increase of at least 10% in sleep latency on the MSLT.
29. The method, the use, or the kit of claim 27, wherein the human being experiences an increase of at least 20% in sleep latency on the MSLT.

30. The method, the use, or the kit of claim 27, wherein the human being experiences an increase of at least 30% in sleep latency on the MSLT.
31. The method, the use, or the kit of claim 27, wherein the human being experiences an increase of at least 40% in sleep latency on the MSLT.
- 5 32. The method, the use, or the kit of claim 27, wherein the human being experiences an increase of at least 50% in sleep latency on the MSLT.
33. The method, the use, or the kit of claim 27, wherein the human being experiences an increase of at least 60% in sleep latency on the MSLT.
34. The method, the use, or the kit of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
10 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, or 33, wherein the human being experiences a decrease of at least 15% in the cataplexy subscore on the UNS.
35. The method, the use, or the kit of claim 34, wherein the human being experiences a decrease of at least 20% in the cataplexy subscore on the UNS.
36. The method, the use, or the kit of claim 34, wherein the human being experiences a
15 decrease of at least 30% in the cataplexy subscore on the UNS.
37. The method, the use, or the kit of claim 34, wherein the human being experiences a decrease of at least 40% in the cataplexy subscore on the UNS.
38. The method, the use, or the kit of claim 34, wherein the human being experiences a decrease of at least 50% in the cataplexy subscore on the UNS.
- 20 39. The method, the use, or the kit of claim 34, wherein the human being experiences a decrease of at least 60% in the cataplexy subscore on the UNS.
40. The method, the use, or the kit of claim 34, wherein the human being experiences a decrease of at least 70% in the cataplexy subscore on the UNS.
41. The method, the use, or the kit of claim 34, wherein the human being has a cataplexy
25 subscore of about 0.